See more : PHAXIAM Therapeutics S.A. (PHXM) Income Statement Analysis – Financial Results
Complete financial analysis of Jeil Pharma Holdings Inc (002620.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jeil Pharma Holdings Inc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Eagle Eye Solutions Group plc (EYE.L) Income Statement Analysis – Financial Results
- AGC Inc. (ASGLF) Income Statement Analysis – Financial Results
- Chesswood Group Limited (CHW.TO) Income Statement Analysis – Financial Results
- Capital Power Corp (CPWPF) Income Statement Analysis – Financial Results
- Filatex Fashions Limited (FILATFASH.BO) Income Statement Analysis – Financial Results
Jeil Pharma Holdings Inc (002620.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jeilpharm.co.kr
About Jeil Pharma Holdings Inc
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. Jeil Pharma Holdings Inc was founded in 1959 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 804.04B | 792.96B | 762.57B | 762.00B | 731.14B | 142.74B | 44.44B | 617.28B | 594.72B | 512.74B | 451.97B | 426.82B | 462.85B | 431.31B | 369.49B | 319.44B | 305.03B |
| Cost of Revenue | 589.46B | 612.48B | 582.06B | 570.76B | 549.16B | 86.28B | 23.13B | 482.15B | 454.50B | 383.86B | 342.55B | 319.04B | 329.68B | 297.37B | 248.37B | 224.11B | 208.14B |
| Gross Profit | 214.58B | 180.48B | 180.51B | 191.24B | 181.98B | 56.46B | 21.31B | 135.13B | 140.22B | 128.88B | 109.42B | 107.78B | 133.17B | 133.94B | 121.11B | 95.33B | 96.89B |
| Gross Profit Ratio | 26.69% | 22.76% | 23.67% | 25.10% | 24.89% | 39.55% | 47.95% | 21.89% | 23.58% | 25.13% | 24.21% | 25.25% | 28.77% | 31.05% | 32.78% | 29.84% | 31.77% |
| Research & Development | 46.04B | 41.57B | 39.67B | 24.73B | 22.45B | 4.51B | 700.86M | 22.36B | 20.30B | 16.77B | 18.09B | 18.26B | 17.59B | 14.49B | 8.35B | 5.21B | 5.32B |
| General & Administrative | 110.41B | 43.21B | 43.30B | 33.62B | 51.91B | 5.73B | 2.58B | 18.08B | 21.56B | 20.84B | 35.27B | 31.85B | 18.83B | 16.11B | 14.22B | 13.82B | 12.48B |
| Selling & Marketing | 37.21B | 36.22B | 43.03B | 46.57B | 38.26B | 18.65B | 7.56B | 28.33B | 28.56B | 25.90B | 10.37B | 11.62B | 21.06B | 22.26B | 27.17B | 26.00B | 26.78B |
| SG&A | 145.79B | 79.43B | 86.33B | 80.19B | 90.17B | 24.39B | 10.15B | 46.41B | 50.12B | 46.74B | 45.64B | 43.47B | 39.89B | 38.37B | 41.40B | 39.82B | 39.27B |
| Other Expenses | 0.00 | 67.03B | 63.48B | 63.84B | 60.35B | 1.19B | 35.76M | 1.73B | 1.61B | 1.68B | 1.41B | 6.50B | 1.03B | -379.10M | 701.66M | 813.17M | -1.13B |
| Operating Expenses | 193.66B | 188.03B | 189.48B | 168.76B | 172.97B | 45.51B | 21.02B | 125.77B | 127.07B | 120.32B | 108.04B | 101.46B | 101.67B | 92.77B | 82.57B | 79.65B | 79.10B |
| Cost & Expenses | 783.22B | 800.51B | 771.54B | 739.52B | 722.13B | 131.79B | 44.15B | 607.93B | 581.57B | 504.19B | 450.60B | 420.50B | 431.35B | 390.14B | 330.95B | 303.76B | 287.24B |
| Interest Income | 1.73B | 499.49M | 247.69M | 171.05M | 336.73M | 147.60M | 82.38M | 41.74M | 152.15M | 243.36M | 371.74M | 740.50M | 1.49B | 1.71B | 1.11B | 720.15M | 612.95M |
| Interest Expense | 10.67B | 5.95B | 3.29B | 3.19B | 2.86B | 1.02B | 18.72M | 775.93M | 572.78M | 658.79M | 753.71M | 753.31M | 319.80M | 294.27M | 621.32M | 615.18M | 634.74M |
| Depreciation & Amortization | 12.56B | 10.91B | 9.17B | 7.63B | 6.81B | 1.66B | 244.53M | 242.95M | 8.46B | 8.54B | 8.37B | 6.54B | 4.48B | 3.75B | 3.03B | 3.61B | 4.48B |
| EBITDA | 33.48B | -72.71B | 6.14B | 43.33B | -78.89B | 12.61B | 5.77B | 6.13B | 21.61B | 19.60B | 10.10B | 19.46B | 38.80B | 49.59B | 47.63B | 30.91B | 30.24B |
| EBITDA Ratio | 4.16% | -8.92% | 1.38% | 5.69% | 3.49% | 8.67% | 16.36% | 3.61% | 4.21% | 4.11% | 2.73% | 4.97% | 9.09% | 11.49% | 13.18% | 9.67% | 9.91% |
| Operating Income | 20.92B | -7.55B | 1.55B | 34.68B | 17.74B | 10.95B | 292.15M | 9.35B | 13.15B | 8.55B | 1.37B | 6.32B | 32.82B | 41.17B | 38.54B | 15.68B | 17.79B |
| Operating Income Ratio | 2.60% | -0.95% | 0.20% | 4.55% | 2.43% | 7.67% | 0.66% | 1.52% | 2.21% | 1.67% | 0.30% | 1.48% | 7.09% | 9.54% | 10.43% | 4.91% | 5.83% |
| Total Other Income/Expenses | -34.90B | -76.31B | 2.85B | 15.48B | -100.34B | -1.16B | 746.01M | -3.51B | 1.29B | 3.28B | 725.23M | 7.31B | 4.49B | 4.38B | 5.43B | 11.01B | 7.33B |
| Income Before Tax | -13.98B | -83.86B | -6.13B | 30.82B | -82.60B | 9.79B | 3.54B | 13.80B | 16.05B | 11.83B | 2.10B | 13.63B | 37.31B | 45.55B | 43.97B | 26.69B | 25.12B |
| Income Before Tax Ratio | -1.74% | -10.58% | -0.80% | 4.04% | -11.30% | 6.86% | 7.96% | 2.24% | 2.70% | 2.31% | 0.46% | 3.19% | 8.06% | 10.56% | 11.90% | 8.35% | 8.23% |
| Income Tax Expense | -740.82M | -715.62M | 6.74B | 15.88B | 13.25B | 2.49B | -489.51M | 5.91B | 6.29B | 9.74B | 1.61B | 2.46B | 10.30B | 20.08B | 15.97B | 9.15B | 11.44B |
| Net Income | -16.25B | -83.15B | -12.87B | 11.43B | -95.85B | 7.07B | 518.82B | 7.89B | 9.76B | 2.10B | 484.39M | 11.17B | 27.01B | 25.47B | 28.00B | 17.53B | 13.67B |
| Net Income Ratio | -2.02% | -10.49% | -1.69% | 1.50% | -13.11% | 4.95% | 1,167.44% | 1.28% | 1.64% | 0.41% | 0.11% | 2.62% | 5.84% | 5.91% | 7.58% | 5.49% | 4.48% |
| EPS | -1.06K | -5.42K | -838.38 | 744.64 | -6.24K | 1.36K | 139.12K | 2.12K | 2.60K | 550.19 | 126.44 | 2.88K | 6.91K | 6.52K | 7.16K | 4.48K | 3.50K |
| EPS Diluted | -1.06K | -5.42K | -838.38 | 744.64 | -6.24K | 1.36K | 139.12K | 2.12K | 2.60K | 550.19 | 126.44 | 2.88K | 6.91K | 6.52K | 7.16K | 4.48K | 3.50K |
| Weighted Avg Shares Out | 15.34M | 15.35M | 15.35M | 15.35M | 15.35M | 5.19M | 3.74M | 2.98M | 3.76M | 3.81M | 3.83M | 3.88M | 3.91M | 3.91M | 3.91M | 3.91M | 3.91M |
| Weighted Avg Shares Out (Dil) | 15.35M | 15.35M | 15.35M | 15.35M | 15.35M | 5.19M | 3.74M | 2.98M | 3.76M | 3.81M | 3.83M | 3.88M | 3.91M | 3.91M | 3.91M | 3.91M | 3.91M |
Source: https://incomestatements.info
Category: Stock Reports